GlassScriptPhysician profile
Holly S Andersen
NPI 1619064706
$1,738.30
in general payments reported to CMS, 2019-2025
24 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $196 · 2021: $46.46 · 2022: $188 · 2023: $267 · 2024: $260 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $254.33 | 2019-2025 | |
| Medtronic Vascular, INC. | $193.31 | 2019 | |
| Boston Scientific Corporation | $160.34 | 2020-2025 | Watchman Access System |
| Amgen INC. | $158.21 | 2019-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $120.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.80 | 2019-2023 | Jardiance |
| Baxter Healthcare | $84.27 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $81.45 | 2024-2025 | Eliquis |
| Lilly USA, LLC | $68.90 | 2023-2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $65.74 | 2019-2020 | |
| Heartflow, INC. | $51.79 | 2025 | |
| Janssen Pharmaceuticals, INC | $48.38 | 2019-2021 | |
| Ge Healthcare | $42.06 | 2019-2021 | |
| Scpharmaceuticals INC. | $41.24 | 2025 | |
| Biobeat USA INC. | $39.22 | 2024 | Bb-613 Bpm Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34.09 | 2025 | Wegovy |
| Philips North America LLC | $31.84 | 2025 | Mcot |
| Cleerly, INC. | $28.17 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Sanofi-Aventis U.S. LLC | $24.19 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $23.55 | 2024 | Arcalyst |
| Astellas Pharma US INC | $22.64 | 2020 | |
| Lantheus Medical Imaging, INC. | $19.61 | 2024 | |
| Pfizer INC. | $18.21 | 2019 | |
| Glaxosmithkline, LLC. | $17.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.